3,449
Participants
Start Date
March 31, 2007
Primary Completion Date
April 30, 2010
Study Completion Date
April 30, 2010
Rivaroxaban (Xarelto, BAY59-7939)
During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
Enoxaparin followed by VKA
Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 h before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
Taipei
Taipei
Kaosiung
Lausanne
Lausanne
Auckland
Bruxelles - Brussel
Vienna
Budapest
Quezon City
Budapest
Vienna
Bruxelles - Brussel
Genéve 14
Rud
Fredrikstad
Johannesburg
Darlinghurst
Auckland
Sydney
St Leonards
Johannesburg
Sydney
Kistarcsa
Johannesburg
Johannesburg
Johannesburg
Kogarah
Sydney
Gosford
Lismore
Lier
Duffel
Garran
Hellerup
Leuven
Box Hill
Melbourne
Clayton
Melbourne
Geelong
Hasselt
Miskolc
Genk
Liège
Redcliffe
Brisbane
Debrecen
Woolloongabba
Southport
Palmerston North
Namur
Woodville South
Salzburg
Adelaide
Yvoir
Perth
Kecskemét
Lucerne
Innsbruck
Wellington South
Fremantle
Szentes
Feldkirch
Worcester
Chur
Trondheim
Somerset West
Cape Town
Cape Town
Aarhus C
Christchurch
Graz
Zurich
Brædstrup
Ghent
Zottegem
Szombathely
Taipei
Jakarta
Pathumwan, Bangkok
Bangkok
Jakarta
Bangkok
Berlin
Berlin
Prague
Safed
Pittsburgh
Girona
Camp Hill
Greifswald
Afula
Milan
Milan
Milan
Medan
Hamburg
Dijon
Varese
Baltimore
Fredericksburg
Besançon
Cremona
Pavia
Vernon
Kladno
Rotenburg (Wümme)
Greensboro
Greensboro
Madrid
Alcorcón
Fuenlabrada
Piacenza
Brest
Nîmes
Venezia
Hanover
Pamplona
Haifa
Haifa
Toulouse
Bordeaux
Paderborn
Miami
Bay Pines
Castelnau-le-Lez
Montpellier
Haifa
Padua
Giessen
Tours
Grenoble
Grenoble
Magdeburg
Bologna
Bandung
Düsseldorf
Taichung
Saint-Etienne
Reggio Emilia
Roanne
Parma
Nantes
Kfar Saba
Essen
Xàtiva
Agen
Angers
Petah Tikva
Semarang
Vandœuvre-lès-Nancy
Mainz
Holon
Witten
Lille
Valenciennes
Soest
Seinäjoki
Frankfurt am Main
Frankfurt am Main
Arras
Clermont-Ferrand
Tel Aviv
Darmstadt
Orthez
Wiesbaden
Chieti
Homburg
Homburg
Strasbourg
Kuala Selangor
Mannheim
Heidelberg
Neckargemünd
Pierre-Bénite
Covington
Tübingen
Little Rock
Oklahoma City
Metz-Tessy
Paris
Paris
Corsicana
Paris
Paris
Paris
Rouen
Rehovot
Karlsbad
Bruchsal
San Antonio
Ashkelon
Amiens
Napoli
München
München
Toulon
Idaho Falls
Beersheba
Salt Lake City
Murray
Augsburg
Limoges
Palermo
Jerusalem
Clamart
Redlands
Colombes
Créteil
Würzburg
Tacoma
Spokane
Beijing
Beijing
Beijing
Beijing
Beijing
Beijing
Beijing
Shenyang
New Delhi
Harbin
Singapore
Shanghai
Shanghai
Shanghai
Suzhou
Singapore
Hangzhou
Mumbai
Pune
Wuhan
Hyderabad
Guangzhou
Guangzhou
Kochi
Kolkata
Daegu
Londrina
Miami
Boston
Albuquerque
Chapel Hill
Uberaba
Curitiba
Botucatu
São Paulo
São Paulo
São Paulo
São Paulo
Sorocaba
Rio de Janeiro
Hong Kong
Wan Chai
London
Winnipeg
London
Ottawa
Toronto
Toronto
Karlovy Vary
Ostrava
Ostrava-Poruba
Prague
Prague
Prague
Usti Nad Lebem
Frederiksberg
Nice
Dresden
Leipzig
Halle
Amsterdam
Arnhem
Dordrecht
Enschede
Groningen
Hoofddorp
Maastricht
Rotterdam
Zwijndrecht
Zwolle
Auckland
Oslo
Quezon City
Bialystok
Bydgoszcz
Gdansk
Katowice
Krakow
Lodz
Lublin
Poznan
Poznan
Torun
Warsaw
Warsaw
Warsaw
Wroclaw
Wroclaw
San Juan
Pretoria
Pretoria
Pretoria
Seoul
Daegu
Seoul
Seoul
Taegu
Barcelona
Barcelona
Terrassa
Borås
Gothenburg
Gothenburg
Jönköping
Sundsvall
Västervik
Plymouth
Chelmsford
Isleworth
London
London
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY
Bayer
INDUSTRY